PMID- 24251799
OWN - NLM
STAT- MEDLINE
DCOM- 20150617
LR  - 20221207
IS  - 1365-2362 (Electronic)
IS  - 0014-2972 (Linking)
VI  - 44
IP  - 2
DP  - 2014 Feb
TI  - Changes in adiponectin level and fat distribution in patients with type 2 
      diabetes.
PG  - 192-9
LID - 10.1111/eci.12207 [doi]
AB  - BACKGROUND: The aim of this study was to assess the impact of standard 
      hypoglycaemic treatment strategies on adiponectin levels and fat distribution in 
      patients with newly diagnosed type 2 diabetes mellitus (T2DM). MATERIAL AND 
      METHODS: This was a prospective observational study of 50 women with newly 
      diagnosed T2DM, aged 64.6 +/- 7.9 years and treated for 12 months with lifestyle 
      modification alone (n = 24) or in combination with metformin (n = 26), according 
      to current standards of diabetic care and clinical practice guidelines. None of 
      the patients required insulin therapy during the entire study period. Total (BF), 
      abdominal (android) and hip (gynoid) fat were measured by dual-energy X-ray 
      absorptiometry at the baseline and after 12 months of treatment. Total 
      adiponectin, glycated haemoglobin (HbA1c) and fasting glucose were measured in 
      3-month intervals. RESULTS: Baseline adiponectin level was low 
      (9.37 +/- 2.81 mug/mL). Lifestyle modifications and metformin produced comparable 
      changes in adiponectin levels, which were not associated with changes in BF, 
      HbA1c, glucose and regional fat depots. Baseline adiponectin was inversely 
      correlated with triglycerides (R = -0.441; P = 0.0007) and the android/gynoid 
      ratio (R = -0.272; P = 0.042). Treatment with metformin was associated with a 
      significant weight reduction (P = 0.033), which resulted from a decrease in BF% 
      (P = 0.044) but was not associated with changes in android and gynoid depots. 
      CONCLUSIONS: In postmenopausal women with newly diagnosed T2DM, lifestyle 
      modifications alone or combined with metformin produced comparable changes in 
      adiponectin levels. Weight reduction in patients treated with metformin was 
      associated with significant decrease in %BF but not in regional fat depots.
CI  - (c) 2013 Stichting European Society for Clinical Investigation Journal Foundation. 
      Published by John Wiley & Sons Ltd.
FAU - Miazgowski, Tomasz
AU  - Miazgowski T
AD  - Department of Hypertension & Internal Medicine, Pomeranian Medical University, 
      Szczecin, Poland.
FAU - Dziwura-Ogonowska, Joanna
AU  - Dziwura-Ogonowska J
FAU - Safranow, Krzysztof
AU  - Safranow K
FAU - Iskierska, Katarzyna
AU  - Iskierska K
FAU - Widecka, Krystyna
AU  - Widecka K
LA  - eng
PT  - Journal Article
PT  - Observational Study
DEP - 20131209
PL  - England
TA  - Eur J Clin Invest
JT  - European journal of clinical investigation
JID - 0245331
RN  - 0 (Adiponectin)
RN  - 0 (Blood Glucose)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Adiponectin/*metabolism
MH  - Adipose Tissue/metabolism/*pathology
MH  - Aged
MH  - Blood Glucose/metabolism
MH  - Body Fat Distribution
MH  - Body Weight/physiology
MH  - Diabetes Mellitus, Type 2/metabolism/*pathology/therapy
MH  - Diet
MH  - Female
MH  - Glycated Hemoglobin/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/therapeutic use
MH  - Metabolic Syndrome/metabolism/pathology
MH  - Metformin/therapeutic use
MH  - Middle Aged
MH  - Postmenopause
MH  - Prospective Studies
MH  - Waist Circumference/physiology
OTO - NOTNLM
OT  - Abdominal fat
OT  - adiponectin
OT  - body fat
OT  - hip fat
OT  - metabolic syndrome
EDAT- 2013/11/21 06:00
MHDA- 2015/06/18 06:00
CRDT- 2013/11/21 06:00
PHST- 2013/05/26 00:00 [received]
PHST- 2013/11/15 00:00 [accepted]
PHST- 2013/11/21 06:00 [entrez]
PHST- 2013/11/21 06:00 [pubmed]
PHST- 2015/06/18 06:00 [medline]
AID - 10.1111/eci.12207 [doi]
PST - ppublish
SO  - Eur J Clin Invest. 2014 Feb;44(2):192-9. doi: 10.1111/eci.12207. Epub 2013 Dec 9.